Literature DB >> 24018014

Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells.

Rita Tanios1, Amira Bekdash, Elias Kassab, Everett Stone, Georges Georgiou, Arthur E Frankel, Ralph J Abi-Habib.   

Abstract

In this study, we target arginine auxotrophy of AML cell lines using human arginase I cobalt-PEG5000. HuArgI(Co)-PEG5000 was cytotoxic to all AML cell lines tested. Mononuclear cells and CD34(+) blasts were not sensitive demonstrating the selectivity of HuArgI(Co)-PEG5000-induced arginine deprivation. Addition of L-citrulline led to the rescue of five cell lines. The four cell lines that were not rescued by L-citrulline did not express argininosuccinate synthetase-1, indicating complete arginine auxotrophy. Inhibition of autophagy increased cell sensitivity to HuArgI(Co)-PEG5000 demonstrating the protective role of autophagy following arginine deprivation. We have shown that AML can be selectively targeted using HuArgI(Co)-PEG5000-induced arginine depletion.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; Arginine; Autophagy; HuArgI(Co)-PEG5000

Mesh:

Substances:

Year:  2013        PMID: 24018014     DOI: 10.1016/j.leukres.2013.08.007

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  23 in total

1.  Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells.

Authors:  Oula Khoury; Noura Ghazale; Everett Stone; Mirvat El-Sibai; Arthur E Frankel; Ralph J Abi-Habib
Journal:  J Neurooncol       Date:  2015-01-08       Impact factor: 4.130

2.  Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent.

Authors:  Ghenwa Nasreddine; Mirvat El-Sibai; Ralph J Abi-Habib
Journal:  Invest New Drugs       Date:  2019-03-18       Impact factor: 3.850

Review 3.  Arginine dependence of tumor cells: targeting a chink in cancer's armor.

Authors:  M D Patil; J Bhaumik; S Babykutty; U C Banerjee; D Fukumura
Journal:  Oncogene       Date:  2016-04-25       Impact factor: 9.867

Review 4.  Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.

Authors:  Regan Stephenson; Ankur Singh
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

Review 5.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 6.  Enzymes in Metabolic Anticancer Therapy.

Authors:  Maristella Maggi; Claudia Scotti
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 7.  Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges.

Authors:  Melissa M Phillips; Michael T Sheaff; Peter W Szlosarek
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

8.  Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells.

Authors:  Z Wang; X Shi; Y Li; J Fan; X Zeng; Z Xian; Z Wang; Y Sun; S Wang; P Song; S Zhao; H Hu; D Ju
Journal:  Cell Death Dis       Date:  2014-12-11       Impact factor: 8.469

9.  Activation of autophagy following [HuArgI (Co)-PEG5000]-induced arginine deprivation mediates cell death in colon cancer cells.

Authors:  Mirna Swayden; Amira Bekdash; Isabelle Fakhoury; Oula El-Atat; Jamila Borjac-Natour; Mirvat El-Sibai; Ralph J Abi-Habib
Journal:  Hum Cell       Date:  2020-09-26       Impact factor: 4.174

Review 10.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.